One-year outcome of ranibizumab for neovascular age-related macular degeneration: A thorough analysis in a real-world clinical setting

摘要

Purpose: To verify the safety and efficacy of ranibizumab in neovascular age-related macular degeneration (nAMD) and factors influencing the outcome in a real-world setting. Methods: Retrospective 12-month follow-up analysis of 100 naive nAMD eyes treated with as-needed ranibizumab. Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), lesion, and leakage size were recorded. Type and characteristics of lesions and indicators of protocol adherence were analyzed. Results: Mean BCVA at baseline was 61.6 ± 14.8 Early Treatment Diabetic Retinopathy Study letters and 59.6 ± 16 at 12 months. Sixty-three eyes maintained or improved BCVA; the number of injections and follow-up visits were 4.8 and 5.1, respectively. First injection and pro re nata retreatments were administered 22.7 and 20.5 days after prescription, respectively. Seventy-two eyes received 3 initial monthly injections. Patients were not reinjected despite BCVA loss 5 letters one or more times in 37% of cases. No adverse events were reported. The CRT diminished by 26 ± 101 μm; choroidal neovascularization size and leakage area increased by 0.53 ± 1.31 mm2 and 0.34 ± 1.33 mm2, respectively. The BCVA gain was correlated with CRT reduction (ρ = 0.24, p = 0.016), mean baseline BCVA (ρ =-0.25, p = 0.01), age (ρ = -0.25, p = 0.01), and decrease in CNV size and leakage area (ρ= 0.56 and ρ = 0.59, respectively, p0.001). Conclusions: Our results compare unfavorably with those of controlled trials. Treatment and followup regimens in real-world settings seem to have a major role in determining outcome. Lower age and BCVA at baseline were associated with better response to treatment.